News for Amedisys, Inc. (AMED)

Market Analysis by covering: Boeing Co, Intel Corporation, Alphabet Inc Class A, Cigna Corp. Read 's Market Analysis on Investing.com

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amedisys (AMED) faces DOJ scrutiny over divestiture amid UnitedHealth merger. Analysts predict a modest 5.61% upside, based on a $100.83 average target

We recently published a list of 11 Best Falling Stocks to Buy According to Analysts.

Robust net income growth from $14.4 million to $61.0 million year-over-year.Significant gain on equity method investment contributing to total income.Operating

Market Analysis by covering: Unitedhealth Group, Amedisys Inc. Read 's Market Analysis on Investing.com

Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Revenue: $594.8 million, slightly below the estimated $596.22 million.Net Income: $61.0 million, significantly up from $14.4 million in the previous year, driv

Summary Amedisys Inc (AMED), a leading healthcare services company, announced its financial results for the first quarter ending March 31, 2025. The company rep

Net service revenue rose to $594.8 million, up from $571.4 million in Q1 2024. Net income attributable to Amedisys (AMED) surged to $61.0 million from $

**media[603717]**

In the dynamic and fiercely competitive business environment, conducting a thorough analysis of companies is crucial for investors and industry enthusiasts. In ...

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

[url=

Comprehensive SWOT analysis based on Amedisys Inc's latest SEC 10-K filing.Financial overview highlights Amedisys Inc's position as a leading healthcare servic

While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Amedisys (AMED) delivered earnings and revenue surprises of -8.57% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Amedisys Inc (AMED), a leading healthcare services company, released its financial results for the fourth quarter and full year ending December 31, 2024, on Feb

Revenue: $598.1 million, slightly below the estimated $598.58 million.Net Loss: $20.4 million, impacted by merger-related expenses and a significant non-cash g